Clinical relevance of human papillomavirus testing in cytopathology

Cytopathology

Volumn 16, Issue 1, 2005, Pages 7-12

  Brink, A A T P ^a   Zielinski, G D ^a   Steenbergen, R D M ^a   Snijders, P J F ^a   Meijer, C J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical carcinoma; Cervical intraepithelial neoplasia; Cytology; Human papillomavirus; Screening

Indexed keywords

ADENOCARCINOMA; CANCER DIAGNOSIS; CANCER SCREENING; CYTOLOGY; CYTOPATHOLOGY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS INFECTION; WART VIRUS;

ADENOCARCINOMA; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTODIAGNOSIS; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 14344263000     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2004.00227.x     Document Type: Review

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Papanicolao GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941;42:193-206.
3. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
4. Meijer CJ, Rozendaal L, van der Linden HC et al. Human papillomavirus testing for primary cervical cancer screening. In: New Developments in Cervical Cancer Screening and Prevention. Franco EL, Monsonego J, (eds). Oxford: Blackwell Science Ltd; 1997:338-47.
5. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003;127:959-68.
6. IARC. IARC confirms efficacy of cervix cancer screening for women 25-65 in reducing mortality. Website IARC 2004: http://www.iarc.fr/ENG/Press_Releases/ pr151a.html. Data last accessed: 16 December 2004
7. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003;201:1-6.
8. Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
9. Clavel C, Masure M, Putaud I et al. Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. J Clin Pathol 1998;51:737-40.
10. Castle PE, Schiffman M, Burk RD et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002;11:1394-9.
11. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998;36:3020-7.
12. Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995;76:1057-62.
13. Jacobs MV, Snijders PJ, van den Brule AJ et al. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-5.
14. van den Brule AJ, Pol R, Fransen-Daalmeijer N et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779-87.
15. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
16. Roda Husman AM, Snijders PJ, Stel HV et al. Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer 1995;72:412-7.
17. Qureshi MN, Rudelli RD, Tubbs RR, Biscotti CV, Layfield LJ. Role of HPV DNA testing in predicting cervical intraepithelial lesions: comparison of HC HPV and ISH HPV. Diagn Cytopathol 2003;29:149-55.
18. Hesselink AT, van den Brule AJ, Brink AA et al. Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples. Cancer 2004;102:11-8.
19. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence - implications for cervical disease progression and monitoring. J Med Virol 2004;73:65-70.
20. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
21. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004;57:388-93.
22. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
23. Hanselaar AG. Criteria for organized cervical screening programs. Special emphasis on The Netherlands program. Acta Cytol 2002;46:619-29.
24. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001;358:1782-3.
25. Clavel C, Masure M, Bory JP et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999;80:1306-11.
26. Fait G, Kupferminc MJ, Daniel Y et al. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral. Gynecol Oncol 2000;79:177-80.
27. Zielinski GD, Snijders PJ, Rozendaal L et al. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol 2001;195:300-6.
28. Clavel C, Masure M, Bory JP et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-23.
29. Hall S, Lorincz A, Shah F et al. Human papillomavirus DNA detection in cervical specimens by hybrid capture: correlation with cytologic and histologic diagnoses of squamous intraepithelial lesions of the cervix. Gynecol Oncol 1996;62:353-9.
30. Herrington CS, Evans MF, Hallam NF et al. Human papillomavirus status in the prediction of high-grade cervical intraepithelial neoplasia in patients with persistent low-grade cervical cytological abnormalities. Br J Cancer 1995;71:206-9.
31. Shlay JC, Dunn T, Byers T, Baron AE, Douglas JM Jr. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears. Obstet Gynecol 2000;96:410-6.
32. Wright TC Jr, Lorincz A, Ferris DG et al. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 1998;178:962-6.
33. Rebello G, Hallam N, Smart G, Farquharson D, McCafferty J. Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study. BMJ 2001;322:893-4.
34. Cuzick J, Szarewski A, Cubie H et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-6.
35. Bulkmans NWJ, Rozendaal L, Snijders PJ et al. POBA-SCAM, a population-based randomised controlled trial for implementation of high-risk HPV testing in cervical screening; Design, methods and baseline data of 44,102 women. Int J Cancer 2003;110:94-101.
36. Zielinski GD, Rozendaal L, Voorhorst FJ et al. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. Gynecol Oncol 2003;91:67-73.
37. Nobbenhuis MA, Meijer CJ, van den Brule AJ et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84:796-801.
38. Zielinski GD, Bais AG, Helmerhorst TJ et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004;59:543-53.
39. Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 2001;93:8-15.
40. Raab SS. Can glandular lesions be diagnosed in pap smear cytology? Diagn Cytopathol 2000;23:127-33.
41. Vizcaino AP, Moreno V, Bosch FX et al. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:536-45.
42. Zielinski GD, Snijders PJ, Rozendaal L et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535-43.
43. Robertson JH, Woodend B. Negative cytology preceding cervical cancer: causes and prevention. J Clin Pathol 1993;46:700-2.
44. Rozendaal L, Walboomers JM, van der Linden JC et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766-9.
45. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
46. Walboomers JM, Husman AM, Snijders PJ et al. Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer. J Clin Pathol 1995;48:728-32.
47. Zielinski GD, Snijders PJ, Rozendaal L et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001;85:398-404.
48. Wallin KL, Wiklund F, Angstrom T et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
49. Petry KU, Menton S, Menton M et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-7.
50. Berkhof J, Bruijne MC, Zielinski GD, Meijer CJ. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer 2004; in press.